ABSTRACT Glomerular basement membrane (GBM) has multifunctions. One of its functions is having nephritogenicity which means the ability of an antigen originally from GBM in causing glomerulonephritis, either in experimental animal or in human being. Recent studies on GBM have revealed that its main component is type IV collagen, consists of 6 different isoforms, α1 (IV) to α 6 (IV) chains. Genetic studies show that all of the six α chains are encoded by genes located in 2, 13, and X chromosomes. Nephritogenic antigen in GBM has been identified as α3, α4, α5 chains. They are molecules of type IV collagen located in globular domain (NC1 domain) at the carboxyl terminus of the type IV collagen of GBM. They are thought to assemble into a α3-α4-α5 (IV) chain helical molecules in human GBM. Other α chains, namely α1 and α2 chain, are not nephritogenic or poorly nephritogenic, while the α6 chain is not located in GBM. The nephritogenicity of GBM has been elucidated as a cause in experimental anti-GMB nephritis, and in Goodpasture and Alport syndromes. 
THE BASEMENT MEMBRANE IS A THIN AND AMORPHOUS specialized extracellular matrix that plays a role in diverse biological events, including embryonic development, maintenance of tissue architecture, protection of tissues and organs from mechanical stress and exogenous factors, tissue remodeling during development and wound healing.
1 Its function is also to serve as barrier for cell movement and molecule filtration particularly obvious in the glomerular basement membrane (GBM), which acts as an ultrafiltration unit, located between the capillary and urinary space within the renal glomerulus. Its function is not only as an ultrafilter to produce a filtrate and supporting tissue against the high blood pressure, but it also has nephritogenicity. Nephritogenicity means the ability of an antigen originally from GBM in causing glomerulonephritis, either in experimental animal or in human being.
Glomerular basement membrane structure
The GBM consists of a rather thick, electron dense central layer (lamina densa, diameter 50 to 100 nm) that is bordered on each side by an electro-lucent lamina rara (diameter 20 -50 nm). Studies on the origin of GBM during embryogenesis show that it is synthesized by both endothelial cells sitting in the capillary and epithelial-like podocytes, which are anchored to the urinary site ( Figure 1A) . The main components of GBM are type IV collagen and other matrices, such as laminin, fibronectin, nidogen and heparan sulfate proteoglycan. These components exist as a supra molecular structure (Figure 1B ) and serve as a scaffold for the binding and alignment of those extracellular matrices.
The suprastructure of type IV collagen comprises protomers (building block units) that are linked to one another through end to-end interaction. The protomers are composed of three α chains and is characterized by three structures i.e. 7 S at the amino terminus, triple helical in the middle region, and NC1 (noncollagenous) domain at the carboxyl terminus ( Figure 1C) . Protomers are associated in head-to-head (NC1 to NC1) fashion to form dimmers, and in tail-totail (7S to 7S) fashion to form tetramers ( Figure 1B) . The classical protomer is composed of two of α1 chains and one of α2 chain, where the chains comprise 1609 and 1707 amino acids residues, respectively.
2,3
Wieslander (1984) was the first who found that the α3 chain of type IV collagen as an auto antigen in Goodpasture syndrome ( Figure 1C and D) . 2 The Goodpasture epitope, the combining site for the pathogenic autoantibody, is recently localized to the carboxyl terminus of the α3 chain ( Figure 1D and E).
Nephritogenic antigens in GBM
Recent studies on basement membrane have revealed that its main component is type IV collagen. There are six different isoforms, namely α1 (IV) to α6 (IV) chain. The complete amino acids sequences of the human 6 chains have already been deduced, as follows: α1 by Brazel et al., α5 by Zhou et al., 7 and α6 by Zhou et al. 8 . A globular domain (NC1 domain) at the carboxyl terminus of the type IV collagen α3 chain α3 (IV) NC1, is thought to be an antigen responsible for anti-GBM nephritis. This is based on the fact that autoantibody to α3 (IV) NC1 can be detected in sera of patients with anti-GBM nephritis by Western blotting and by enzyme immunoassay using recombinant α3 (IV) NC1 protein. [9] [10] [11] [12] In addition, α4 (IV) NC1 is also thought to be an antigen responsible for anti-GBM nephritis, since experimental anti-GBM nephritis can be induced in rats by injection of synthetic peptide that consisted of parts of the sequences of human α3 (IV) NC1 or α4 (IV) NC1. 13 Rauf et al.
14 described the nephritogenicity of NC1 fractions from bovine kidney, lung, and placenta by using monoclonal antibodies. They found that nephritogenicity was apparently a property of α3 -α5(IV) NC1. This finding was supported by Sado, 15 who found that α3 -α5 (IV) NC1 purified from human renal basement membrane could induce antiglomerular basement membrane antibody glomerulonephritis in rats. On the contrary, α1 and α2(IV) NC1 were not nephritogenic, because NC1 fraction from placental basement membrane which contained of a large amount of α1 -2(IV) NC1, either from bovine, 14 or human, 15 ( Figure 2 ) could not cause anti- GBM nephritis (Figure 3) . Also, α6 (IV) NC1 does not seem to be responsible for the induction of the anti-GBM nephritis, because the α6(IV) chain is absent in the GBM, either in human 16 or in bovine 14. Therefore, out of the six α chains only three chains, namely α3 (IV), α4 (IV), and α5 (IV), are nephritogenic antigens.
Chromosomal location of collagen IV genes
Genetic studies show that all of the six α chains are encoded by genes located in 2, 13, and X chromosomes. Since the first two human collagen IV genes found, COL 4 A1 and COL 4 A2 were assigned to the same chromosomal locus, namely 13q34. It was hypothesized that additional genes belong to the same subclass are also located in the same region, like in other multi genes families of globin and histone genes, but the other four genes turned out to be on different chromosomes. COL 4 A3 and COL 4 A4 were located on 2q 35-q 37 while COL 4 A5 and COL 4 A6 on Xq 22.1 That means the three paired genes were found to reside at the three different chromosomal regions, as is showed in Figure 4 . 
The nephritogenicity of GBM in various renal diseases Experimental animal
The nephritogenicity of GBM was first reported in 1962 by Steblay, 17 who injected multiple doses of insoluble GBM emulsified with adjuvant to sheep, which caused experimental anti-GBM nephritis. Since then, many attempts have been done with success in isolating nephritogenic antigen, either in experimental animal or in human being.
9,18
There are 2 types of experimental anti GBM nephritis. The active type is revealed by a single injection of a soluble emulsion of nephritogenic antigen in rats 19, 20 while the passive type is yielded by the injection of either homologous polyclonal or monoclonal antibodies to GBM of type IV collagen of GBM.
21,22

Goodpasture syndrome (GPS)
Goodpasture syndrome is characterized by a rapidly progressive glomerulonephritis, anti-GBM antibody formation, and pulmonary hemorrhage. This disease is a lethal form of autoimmune disease, because of renal failure or pulmonary hemorrhage. Wieslander for the first time reported that localization of the Goodpasture's antigen is in the noncollagenous region of type IV collagen in GBM. 10 Goodpasture's antigen is defined as the antigen that react specifically with antibody in the sera of patients with Goodpasture's syndrome. It was then reported that the Goodpasture's antigen is the α3 (IV) NC1.
3 ( Figure 1 ) Another work analyzes antigen fractions prepared from bovine and human renal basement membranes shows that soluble fractions containing NC1 domains of the α3, 4 and 5 are strongly nephritogenic, whereas soluble fraction containing the NC1 domains of the α1 and 2 chains show no or poor nephritogenicity. 15, 16 This suggests that besides α3 chain, α4 and 5 are also involved in the pathogenesis of experimental Goodpasture syndrome.
Alport syndrome
Alport syndrome is an inherited disease characterized by sensorineural deafness and hematuria with relentless progression to end-stage renal disease. The renal lesion is characterized by ultrastructural abnormalities namely thinning, thickening, diffuse splitting and multi lamination of the lamina densa in the GBM. Extensive research over the past decades have extended our knowledge on the clinical, ultrastructural and genetic features of Alport syndrome, and have elucidated the molecular genetic basis of the disease. Alport syndrome is now understood as a disease of specific type IV collagen chain, caused by gene mutation of the α3 (IV), α4 (IV), and α5 (IV) of type IV collagen.
The genes of the α3 (IV) and α4 (IV) chains are on chromosome 2 in a head-to-head fashion, whereas the gene for the α5 (IV) chain resides on chromosome X.
The distribution pattern of the six α chains suggests that there are three combinations of α chains, 1 namely combination of two of α 1 and one of α 2 chains (α1/α1/α2), combination of α3, α4, and α5 chains (α3/α4/α5), and combination of two of α5 and one of α6 (α5/α5/α6). 23 In the kidney of male patients with typical X-linked Alport's syndrome, the α3 to α6 chains are missing, suggesting that molecules having the α3/α4/α5 and (α5/α5/α6) are absent. In the kidney of female patients with X-linked Alport syndrome, a discontinuous pattern (mosaic pattern) is observed. This is due to inactivation of chromosome X. One of the two chromosomes X is inactivated randomly in a mosaic pattern in the whole body; so if the normal X chromosome is activated, the α3/ α4/α5 and (α5/α5/α6) are present, and if the abnormal X chromosome is activated, no such combinations of molecules is present. On the contrary, when gene mutations are present in the genes encoding the α3 or α4 chain, the mode of inheritance is an autosomal recessive form. The consequence of this mutation is no α3/α4/α5 present in the GBM.
24
The absence or the decrease of the content of α3/α4/α5 molecules in the GBM will lead the disease, to both, X-linked and autosomal recessive forms. This fact is now used for diagnosis of Alport's syndrome by immunohistochemical staining of cryostat section and paraffin-embedded section with monoclonal antibodies.
25-27
From the clinical point of view, based on the presence of molecules α 3/α 4/α 5 which are nephritogenic, a small number of patients (about 5 %) with Alport syndrome develops Goodpasture syndrome after renal transplantation.
28 This is because the Goodpasture antigen (α3 chain) is absent in the kidney of patients with Alport syndrome, so consequently the α3 chain in the new kidney is recognized as a foreign antigen and leads to the antibody anti-GBM formation.
